Top Tweets for #BlueBirdBio

almost 2 years ago

$BLUE $PFE $HTGC #BlueBirdBio #BioTech #SickleCell #Mergers #Acquisitions #Disease #Drugs #RateCutEnvironment #SmallCaps $XBI $IBB $SPY $QQQ $IWM $IWN $HTGC Loan Agreement with $BLUE $BlueBirdBio via MileStone payouts. Renegotiated certain terms of its loan agreement with Hercules Capital, Inc. $HTGC and is eligible to receive two future tranches totaling $50 million. contingent upon achievement of patient start and product delivery milestones and completion of additional financing. $BalanceSheet Cash Position: $193M Cash Runway into Q2 2025 with two MileStone payouts of $50M by 2024 year end if it meets its 2024 guidance.

almost 2 years ago

$BLUE #BioTech #SickleCell #Medicaid #BlueBirdBio #MergersAndAcquisitions Consolidating price action. 1 hour & 4 hour. $BLUE $PFE $SPY $QQQ $IBB $XBI $IWM $IWN $PFE Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4B buyout of Global Blood Therapeutics in 2022. $PFE said on Wednesday it was withdrawing its #SickleCell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication & deaths. https://t.co/MQ8JFms9cR #Notes Pfizer $PFE has been exploring other treatments for sickle cell disease, but with the withdrawal of Oxbryta (voxelotor), the immediate options within their portfolio are limited. Oxbryta was the only drug $PFE had in the #SickleCell Space. $BLUE #BlueBirdBio Updates. Current as of August 14, 2024: 1. #2024Guidance The Company anticipates approximately 85 patient starts (cell collections) in 2024 combined across its portfolio of three FDA approved therapies 👉LYFGENIA: Approved for #SickleCell ZYNTEGLO: Approved for the treatment of beta-thalassemia in patients who require regular blood transfusions. SKYSONA: Approved for the treatment of cerebral adrenoleukodystrophy (CALD), a rare neurological disorder affecting boys. 2. #SickleCell Successfully completed manufacturing and release testing for first commercial LYFGENIA patient and the first infusion is being scheduled. 3. Rapid acceleration projected for ZYNTEGLO following the recent approval of additional manufacturing capacity. https://t.co/b8RVg0cYk2

risenfit's tweet photo. $BLUE #BioTech #SickleCell #Medicaid #BlueBirdBio #MergersAndAcquisitions Consolidating price action.
1 hour & 4 hour. $BLUE $PFE
$SPY $QQQ $IBB $XBI $IWM $IWN

$PFE Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4B buyout of Global Blood Therapeutics in 2022.

$PFE said on Wednesday it was withdrawing its #SickleCell disease treatment Oxbryta from all markets where it is approved,

citing risks of a painful complication & deaths.
https://t.co/MQ8JFms9cR

#Notes
Pfizer $PFE has been exploring other treatments for sickle cell disease, but with the withdrawal of Oxbryta (voxelotor), the immediate options within their portfolio are limited.

Oxbryta was the only drug $PFE had in the #SickleCell Space.

$BLUE #BlueBirdBio Updates.
Current as of August 14, 2024:

1. #2024Guidance
The Company anticipates approximately 85 patient starts (cell collections) in 2024 combined across its portfolio of three FDA approved therapies
👉LYFGENIA: Approved for #SickleCell
ZYNTEGLO: Approved for the treatment of beta-thalassemia in patients who require regular blood transfusions.
SKYSONA: Approved for the treatment of cerebral adrenoleukodystrophy (CALD), a rare neurological disorder affecting boys.

2. #SickleCell
Successfully completed manufacturing and release testing for first commercial LYFGENIA patient and the first infusion is being scheduled.

3.
Rapid acceleration projected for ZYNTEGLO following the recent approval of additional manufacturing capacity.

https://t.co/b8RVg0cYk2

0

3

0

4K

0

3

0

7K

almost 2 years ago

$BLUE #BioTech #SickleCell #Medicaid #BlueBirdBio #MergersAndAcquisitions Consolidating price action. 1 hour & 4 hour. $BLUE $PFE $SPY $QQQ $IBB $XBI $IWM $IWN $PFE Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4B buyout of Global Blood Therapeutics in 2022. $PFE said on Wednesday it was withdrawing its #SickleCell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication & deaths. https://t.co/MQ8JFms9cR #Notes Pfizer $PFE has been exploring other treatments for sickle cell disease, but with the withdrawal of Oxbryta (voxelotor), the immediate options within their portfolio are limited. Oxbryta was the only drug $PFE had in the #SickleCell Space. $BLUE #BlueBirdBio Updates. Current as of August 14, 2024: 1. #2024Guidance The Company anticipates approximately 85 patient starts (cell collections) in 2024 combined across its portfolio of three FDA approved therapies 👉LYFGENIA: Approved for #SickleCell ZYNTEGLO: Approved for the treatment of beta-thalassemia in patients who require regular blood transfusions. SKYSONA: Approved for the treatment of cerebral adrenoleukodystrophy (CALD), a rare neurological disorder affecting boys. 2. #SickleCell Successfully completed manufacturing and release testing for first commercial LYFGENIA patient and the first infusion is being scheduled. 3. Rapid acceleration projected for ZYNTEGLO following the recent approval of additional manufacturing capacity. https://t.co/b8RVg0cYk2

almost 2 years ago

$BLUE Updates! $XBI $IBB $IWM $IWN $SER $RSLS $BFRG $TBIO $CTOR $VTGN $CRBU $SRRK $ATRA $ARQT $VERU In march, $BLUE sold off on accounting errors. $BLUE had to restate its financials for 2022 and 2023, Q1 & Q2 2024, after finding several accounting errors. #Update $BLUE has completed the restatement of its consolidated financial statements for the year ended: 2022 1) December 31, 2022, and for each of the first three quarters of 2022. 2023 2) filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) 2024 Q1 3) restated information, and Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”). #Note The restatements had NO IMPACT on the Company’s CASH position or REVENUE. 2024 Q2 4) $BLUE is currently working on Q2 2024 restatement, and is working expeditiously to complete this filing. https://t.co/sePneEW1OK #FurtherUpdates $BLUE will be having a meeting of stockholders on November 6, 2024. The company will be voting on: 👇 A) the approval of named executive officer compensation (Prop 1) B) the approval of an amendment to our Amended and Restated Certificate of Incorporation. (Prop 2) 👉C) to provide for the exculpation of officers for certain breaches of fiduciary duty**** (Prop 3) 👉D) Incorporation to effect a reverse stock split of our common stock at a ratio ranging from any whole number between 1-for-15 and 1-for-20, as determined by our Board of Directors (Prop 4) E) the approval of an amendment and restatement of our 2023 Incentive Award Plan (Prop 5) F) increase the number of shares of our common stock authorized for issuance thereunder ("Proposal 5"), G) the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. (Prop 6) https://t.co/m5zKv6d6lx

0

4K

0

3

0

4K

BioSpace @biospace

almost 2 years ago

About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D. https://t.co/iauMN8MiDQ #layoffs #bluebirdbio

0

1

0

1

520

almost 3 years ago

Could $EDIT be the biggest winner of $CRSP $BLUE DUEL! But NOW #bluebirdbio incredible run is finally HEADED out to 10s of thousands patients drastically reducing healthcare needs and making co. PROFITABLE! WIN WIN 🥇

1

2

0

698

almost 3 years ago

$BLUE #biotech with decades of r&D, 3 approved transformative #gene therapies that cure trades @ $3, below 5% off not so distant highs! how would you value startups in ph 1/2 days from INN? $ 0?! #bluebirdBIO treating just 1000 patients (1% of population) - is $2-3B alone!

0

1

0

277

Medical Dialogues @medicaldialogs

almost 3 years ago

$BLUE Some if not most "physicians and patients maybe more comfortable with Bluebird #Lyfgenia - vector technology which dates back to 1990s!", #FDA black box label potentially quite deceiving here! Today was a HUGE opportunity to BUY sub $3 #BluebirdBio on $MS upgrade! $EDIT win

Adam Feuerstein ✡️

@adamfeuerstein

almost 3 years ago

Tough road ahead for Bluebird Bio $BLUE despite FDA approval for sickle cell therapy https://t.co/SjwDpIEVE6 via @brittanytrang $VRTX $CRSP

2

21

2

5

10K

0

2

0

1

573

almost 3 years ago

US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy https://t.co/QPsgYQxGaY #usfda #bristolmyerssquibbb #ristolmyerssquibbnews #2seventybio #bloodcancertherapy #abecma #multiplemyeloma #bluebirdbio #healthnews #mednews #medicalnews #medicaldialogues #medtwitter

0

2

0

183

Dr. Kaouthar Lbiati

@kaoutharlbiati

almost 3 years ago

If approved, #exacell by #Vertex would be d first #genetherapy with #CRISPR gene-editing technique to treat sickle cell disease. By Dec. 20, F.D.A. will decide on a second gene therapy for sickle cell by #BluebirdBio. LT follow up >15y is a must @NYTimes https://t.co/iwI4BihVKO

0

2

0

1

256

over 3 years ago

Is $BLUE CAR-T and #genetherapy pioneer worth only a fraction of all investments pre- and post-2013 IPO, and the value of their three approved treatments? Just how short sighed current market is. #Bluebirdbio cos clearly high single/low double $B’s market cap co. $IBB #crispr

1

3

1

0

399